Spots Global Cancer Trial Database for Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Official Title: Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors
Study ID: NCT00413075
Interventions
Study Description
Brief Summary: This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yale New Haven Hospital, New Haven, Connecticut, United States
Columbia University - Herbert Irving Cancer Center, New York, New York, United States
New York University Cancer Institute, New York, New York, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Research Facility, Copenhagen, , Denmark
Research Facility, London, Surrey, United Kingdom
Contact Details
Name: enquiries@topotarget.com
Affiliation: Valerio Therapeutics
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
